Real-World Effectiveness of JAK Inhibitors for Alopecia Totalis and Alopecia Universalis: A Single-Center Experience

This study evaluated the effectiveness and safety of JAK inhibitors in treating alopecia totalis (AT) and alopecia universalis (AU) in a real-world setting at a single center in China. It included 45 patients treated with tofacitinib, ritlecitinib, or baricitinib. The primary endpoint was achieving a Severity of Alopecia Tool (SALT) score of 20 or less at week 24. Results showed significant improvement in SALT scores over time, with ritlecitinib achieving the highest response rate of 50% by week 24, followed closely by tofacitinib at 48%, and baricitinib at 16.7%. No serious adverse events were reported, supporting the use of JAK inhibitors as a viable treatment option for severe alopecia areata.